<?xml version="1.0" encoding="UTF-8"?>
<p>While patients with CHIKV infection may exhibit a variety of symptoms such as rash, chills, headache, nausea, photophobia, and vomiting, it is characterized by acute high fever, and severe polyarthralgia 
 <xref rid="pntd.0003101-Borgherini1" ref-type="bibr">[10]</xref>. Persistent arthralgia can remain for years 
 <xref rid="pntd.0003101-Borgherini2" ref-type="bibr">[11]</xref>–
 <xref rid="pntd.0003101-Schilte1" ref-type="bibr">[14]</xref> and it has been shown to be a major cause of long-term discomfort 
 <xref rid="pntd.0003101-Queyriaux1" ref-type="bibr">[15]</xref>. Fatalities following CHIKV infection are rare, but have been shown to occur 
 <xref rid="pntd.0003101-Gerardin1" ref-type="bibr">[16]</xref>–
 <xref rid="pntd.0003101-Renault1" ref-type="bibr">[18]</xref> as a result of severe neurologic disease 
 <xref rid="pntd.0003101-JaffarBandjee1" ref-type="bibr">[19]</xref>–
 <xref rid="pntd.0003101-Tandale1" ref-type="bibr">[21]</xref>. To date, CHIKV continues to pose a threat to several countries in the world and continues to cause outbreaks in India and Southeast Asia, resulting in persistent morbidity and consequently considerable economic losses. Therefore, vaccine development remains a high priority. Currently, there are no licensed CHIKV vaccines available, although there are several experimental candidate vaccines are under investigation.
</p>
